Target intelligence / Profile preview

Stem cell replacement therapy (None)

Target
None
Molecular classification
Cell type, Mesenchymal stem cell, Hematopoietic stem cell, Induced pluripotent stem cell
01

Overview

Stem cell replacement refers to the process of administering stem cells into a patient to regenerate, repair, or replace damaged tissues or cells. These cells possess unique abilities, including self-renewal, differentiation into specialized cell types, and modulation of immune responses. Stem cell therapy is used for a range of diseases, from hematological malignancies and neurodegenerative disorders to autoimmune conditions and traumatic injuries. The therapeutic action involves homing to damaged areas, differentiating into needed cell types, releasing bioactive molecules to regulate inflammation and apoptosis, and promoting tissue regeneration. While research is active and many applications are promising, stem cell therapy faces challenges regarding efficacy, safety, and long-term outcomes.

Other names
Stem cell therapyStem cell transplantationCell replacement therapyRegenerative cell therapy
02

Mechanism of action

Stem cell replacement therapy works through several mechanisms: homing and engraftment in damaged tissue, differentiation into specific cell types, paracrine signaling (release of growth factors, chemokines), and immunomodulation (suppressing inflammatory responses).

03

Biological functions

Cell proliferationCell differentiationTissue regenerationApoptosis inhibitionImmunomodulationAnti-inflammation
04

Disease associations

Cancer (especially blood cancers via bone marrow transplant)Neurodegenerative disease (ALS, Alzheimer’s)Cardiovascular disease (heart attack, heart failure)InflammationBlood disorders (anemia, leukemia)Other (wound healing, orthopedic injuries, autoimmune diseases, digestive disease)
05

Safety considerations

Tumorigenicity (possibility of forming tumors)Graft-versus-host disease (especially allogeneic transplants)Immune rejectionInfection riskPoor engraftmentPotency and purity variability
06

Interacting drugs

Mobilizing agents for stem cell transplantation (G-CSF, plerixafor)

2 more in the full profile.

07

Biomarkers

CD34+, CD45+, CD90+, CD105+ (depends on stem cell type and quality control)Engraftment markers (e.g., chimerism assays post-transplant)Some disease-specific functional assessments

Beyond the preview

Go deeper on Stem cell replacement therapy (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stem cell replacement therapy (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call